Marco Meglio

The innovative nonsurgical device has previously received market authorization to treat gait deficit due to mild-to-moderate symptoms from multiple sclerosis.

The agent’s safety profile has been studied in more than 1200 individuals to date across several inflammatory diseases, with data indicating that the high selectivity of fenebrutinib may limit off-target effects.

Patients with focal seizures showed a median 25.2% reduction in the frequency of focal seizures, the most common seizure type in patients with tuberous sclerosis complex.

Multivariable logistic regression models found age to be the only characteristic associated with the risk of CELs at baseline in all datasets, with a higher age associated with a lower risk of CELs.

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine provided context on greenhouse spaces and their preventive benefits in Alzheimer disease.

Microvesicles excellently discriminated between the relapsing-remitting MS and control groups and between radiologically isolated syndrome and unspecific brain lesions.

Investigators identified 4 susceptible loci with large effect sizes, one of which has previously been associated with migraine.

Individuals with chronic and episodic migraine saw improvements in patient-reported outcomes such as MSQoL, EQ-5D-5L, PGIC, WPAI, and the 9-Item Patient Health Questionnaire.

Patients with AQP4+NMOSD with long cord lesion showed higher annualized atrophy rate of normalized grey matter volume compared with those without long cord lesion.

After years of only off-label, wake-promoting therapies available for use, the FDA has approved the first treatment for idiopathic hypersomnia, JZP-258 (Xywav; Jazz).

The association of increased EVT rates was noted with the initiation of online training and EMS dissemination of the policy in September 2018, 2 months in advance of formal implementation of prehospital protocol.

Two unblinded interim analyses by the Data Monitoring Committee are planned to assess the futility of reldesemtiv, with the first occurring 12 weeks after one-third of the sample size is randomized.

The professor of health science at the Medical University of South Carolina discussed robust results from the phase 3 ADMET 2 study evaluating methylphenidate to treat apathy in Alzheimer disease.

Adverse reactions were consistent with the known side effect profile of sodium oxybate and were generally mild or moderate in new data from the REST-ON trial (NCT02720744).

Investigators obtained a molecular diagnostic yield of 39% in 66 sequential, unselected individuals with diverse presentations of rare neurogenetic disorders when using a model that integrates additional assays.

A lateralization effect was observed for patients with left temporal lobe epilepsy, as their BrainAGE values more closely resembled control group values following surgery.

Mike Detke, MD, PhD, chief medical officer, Cortexyme, provided context on atuzaginstat’s high ceiling in Alzheimer disease, its regulatory path, and its unique dental substudy.

The direct transfer protocol had greater decreases in the median door-to-arterial puncture time and door-to-reperfusion time in comparison to conventional workflow in acute ischemic stroke care.

There was no evidence of increased risk of suicidal ideation or attempt overall or for any individual antiseizure medication in a meta-analysis of 5 newer ASMs.

Homeostatic equilibrium was achieved with CNM-Au8 across essential energetic metabolites, including adenosine triphosphate, intracellular phosphorous, phosphocholine, and phosphorylation potential index.

LX1004 and APB-102 are currently in the early phases of research to treat CLN2 Batten disease and SOD1 amyotrophic lateral sclerosis, respectively.

Led by a team of top talents, NYU Langone’s Comprehensive Epilepsy Center’s contributions to drug development and improving the quality of life for patients stand among the field's most important.

Among independent variables including DMT group, time from COVID-19 infection, total IgG level, age, sex, obesity, and COVID-19 severity, only the anti-CD20 group was associated with decreased odds of positive serology.

The chief medical officer of Cortexyme discussed the company’s investigational agent atuzaginstat, its mechanism of action, and the findings of the phase 2/3 GAIN trial.

The model discovered nonsequential, overlapping disease progression trajectories, supporting the use of nondeterministic disease progression models.

Aquestive does not anticipate a need for any additional studies and is preparing for the commercial launch of Libervant in the first half of 2022, if approved.

Of those who reported new or worsening neurological symptoms, 77.8% didn’t require any additional medication to treat their symptoms.

Higher percentages of infants were event-free and were classified as having a motor-milestone response at month 12 than in historical cohorts.

The label now includes the use of ultrasound as a muscle localization technique in adults with spasticity, and includes muscles of the elbow, forearm, hand, and thumb.

The ICARE AD-US trial is expected to enroll 6000 participants, with at least 16% of the population aimed at including those from underrepresented communities. The unrelated confirmatory phase 4 trial is still in the process of being designed.